Cubist Systematic Strategies LLC purchased a new stake in Smith & Nephew plc (NYSE:SNN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 43,255 shares of the medical equipment provider's stock, valued at approximately $1,063,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SNN. Principal Securities Inc. raised its stake in shares of Smith & Nephew by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 691 shares during the last quarter. R Squared Ltd bought a new stake in Smith & Nephew in the fourth quarter valued at approximately $41,000. National Bank of Canada FI increased its stake in Smith & Nephew by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock valued at $41,000 after purchasing an additional 446 shares in the last quarter. Hara Capital LLC boosted its holdings in shares of Smith & Nephew by 391.4% in the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 1,957 shares during the period. Finally, Blue Trust Inc. boosted its holdings in shares of Smith & Nephew by 26.0% in the fourth quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock valued at $144,000 after buying an additional 1,213 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on SNN. HSBC cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, April 25th. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research report on Wednesday, March 12th. Canaccord Genuity Group upped their price target on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research report on Thursday, May 1st. Finally, Hsbc Global Res lowered shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Six research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Smith & Nephew has a consensus rating of "Hold" and a consensus price target of $28.00.
Check Out Our Latest Analysis on SNN
Smith & Nephew Stock Performance
Shares of SNN traded up $0.08 during trading hours on Friday, hitting $28.83. The company had a trading volume of 397,991 shares, compared to its average volume of 805,276. The firm has a market cap of $12.63 billion, a price-to-earnings ratio of 13.35, a PEG ratio of 1.26 and a beta of 0.68. The business has a fifty day moving average of $27.42 and a 200-day moving average of $26.28. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63.
Smith & Nephew Increases Dividend
The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be given a $0.447 dividend. The ex-dividend date is Friday, March 28th. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. Smith & Nephew's dividend payout ratio is presently 41.20%.
About Smith & Nephew
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Articles
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
